Importantly, compared to the wild-type counterparts, KRAS-mutant tumors showed higher expression of PD-L1, with the median PD-L1 tumor proportion scores ranging between 30–60% and 5–35% in patients with and without KRAS mutations, respectively (21, 24). The gene discussed is KRAS; the disease is neoplasm.